Prevention of venous thromboembolism recurrence

Prevention of venous thromboembolism recurrence refers to extended or secondary thromboprophylactic management aimed at preventing repeated thrombotic occlusions in the deep venous system or pulmonary arterial circulation among patients with a prior documented episode of deep vein thrombosis or pulmonary embolism The condition primarily impacts the vascular and cardiopulmonary systems, with elevated susceptibility occurring in populations exhibiting persistent prothrombotic risks, inheritable or...

Prevention of venous thromboembolism recurrence refers to extended or secondary thromboprophylactic management aimed at preventing repeated thrombotic occlusions in the deep venous system or pulmonary arterial circulation among patients with a prior documented episode of deep vein thrombosis or pulmonary embolism

Prevention of venous thromboembolism recurrence refers to extended or secondary thromboprophylactic management aimed at preventing repeated thrombotic occlusions in the deep venous system or pulmonary arterial circulation among patients with a prior documented episode of deep vein thrombosis or pulmonary embolism The condition primarily impacts the vascular and cardiopulmonary systems, with elevated susceptibility occurring in populations exhibiting persistent prothrombotic risks, inheritable or...

The condition primarily impacts the vascular and cardiopulmonary systems, with elevated susceptibility occurring in populations exhibiting persistent prothrombotic risks, inheritable or acquired thrombophilias, active malignancy, or prior unprovoked events

Pathophysiologically, it is driven by Virchow’s triad—endothelial injury, venous stasis, and systemic hypercoagulability—leading to inappropriate thrombin generation and fibrin deposition that can trigger progressive venous insufficiency, recurrent vascular obstruction, chronic thromboembolic pulmonary hypertension, or fatal thromboembolic embolization

Pathophysiologically, it is driven by Virchow’s triad—endothelial injury, venous stasis, and systemic hypercoagulability—leading to inappropriate thrombin generation and fibrin deposition that can trigger progressive venous insufficiency, recurrent vascular obstruction, chronic thromboembolic pulmonary hypertension, or fatal thromboembolic embolization

Pathophysiologically, it is driven by Virchow’s triad—endothelial injury, venous stasis, and systemic hypercoagulability—leading to inappropriate thrombin generation and fibrin deposition that can trigger progressive venous insufficiency, recurrent vascular obstruction, chronic thromboembolic pulmonary hypertension, or fatal thromboembolic embolization